Aspen Neuroscience, Inc. (NASDAQ:ASPE) Executive Chair Hasnain Faheem filed a statement of changes in beneficial ownership on November 9, 2026, reporting the acquisition of 321,672 shares of common stock on November 5, 2026, through a fully vested restricted stock unit award.

Key Highlights

  • Reporting person: Hasnain Faheem, Executive Chair and Director of Aspen Neuroscience, Inc.
  • Transaction: Acquisition (Code A) of 321,672 shares of common stock at $0.00 price on November 5, 2026.
  • RSU award: The shares were described as "100% vested upon grant" and are to be delivered upon settlement of a restricted stock unit award under Faheem's executive chair offer letter.
  • Settlement timing: The units will settle in one lump sum on the first qualifying trading day in calendar year 2027, subject to lock-up expiration and insider trading policy conditions, but no later than December 31, 2027.
  • Direct beneficial ownership following transaction: 348,330 shares held directly.
  • Indirect ownership: 36,349 shares held indirectly by family trust.

Faheem's RSU Settlement and Ownership Position at Aspen Neuroscience

According to the filing, Hasnain Faheem acquired 321,672 shares of Aspen Neuroscience common stock on November 5, 2026, under transaction code "A," at a price of $0.00. The shares represent a restricted stock unit award granted under his executive chair offer letter and were described in the filing as "100% vested upon grant."

Aspen Neuroscience, Inc. is a San Diego-based biotechnology company. The filing identifies the issuer's ticker as ASPE on NASDAQ. Following the reported transaction, Faheem directly beneficially owns 348,330 shares of common stock. He also holds 36,349 shares indirectly through a family trust, as disclosed in Table I of the filing.

The filing states that actual delivery of the 321,672 shares will occur in one lump sum on the first qualifying trading day in calendar year 2027, subject to two conditions: the expiration or termination of the lock-up period applicable under Faheem's lock-up agreement with the underwriters of the company's initial public offering, and his being permitted to sell shares in the open market under the issuer's insider trading policy. The filing notes the settlement will occur "in all cases no later than December 31, 2027." The filing was signed by Jeffrey L. Boerneke as attorney-in-fact on November 9, 2026.

What Was Disclosed

Hasnain Faheem, Executive Chair and Director of Aspen Neuroscience, Inc. (NASDAQ:ASPE), reported a November 5, 2026 acquisition of 321,672 fully vested RSU shares at $0.00, bringing his direct beneficial ownership to 348,330 shares, with an additional 36,349 shares held indirectly through a family trust.